CCM trades at Wall Street's consensus target of —.
Last 12 months price action with 12-month analyst target path
The base valuation assumes CCM achieves its forward estimates and maintains a stable P/E multiple of 1.1x. This scenario reflects the blended consensus of 2 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of July 7, 2026, Concord Medical Services Holdings Limited (CCM) has a Wall Street consensus price target of N/A, based on estimates from 2 covering analysts. The company has a market capitalization of $666917.
Analyst price targets range from a low of N/A to a high of N/A.
The current analyst consensus rating is Buy, with 2 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, CCM trades at a trailing P/E of -0.1x and forward P/E of 1.1x. Analysts expect EPS to grow +100.4% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
RDNTRadNet, Inc. | $5.4B | $68.92 | $85.00 | +23.3% | Buy | 133.6x | 11 |
USPHU.S. Physical Therapy, Inc. | $1.1B | $73.38 | $96.00 | +30.8% | Buy | 26.2x | 13 |
AMSFAMERISAFE, Inc. | $648M | $34.65 | $44.50 | +28.4% | Buy | 16.5x | 6 |
ARAYAccuray Incorporated | $32M | $0.27 | — | — | — | — | — |
MLABMesa Laboratories, Inc. | $567M | $102.56 | $94.00 | -8.3% | Hold | 11.3x | 8 |
ISRGIntuitive Surgical, Inc. | $153.3B | $432.83 | $597.78 | +38.1% | Buy | 41.4x | 55 |
MDTMedtronic plc | $106.6B | $83.06 | $95.80 | +15.3% | Buy | 13.9x | 51 |
EWEdwards Lifesciences Corporation | $54.8B | $95.18 | $97.45 | +2.4% | Buy | 31.6x | 48 |
SYKStryker Corporation | $120.1B | $313.38 | $387.46 | +23.6% | Buy | 20.9x | 51 |
HCAHCA Healthcare, Inc. | $92.5B | $417.07 | $504.73 | +21.0% | Buy | 13.8x | 46 |
Quick answers to the most common questions about buying CCM stock.
The consensus price target for CCM is $N/A, close to the current price of $4.58 (N/A% implied move). Based on 2 analyst estimates, the stock appears fairly valued near current levels.
CCM has a consensus rating of "Buy" based on 2 Wall Street analysts. The rating breakdown is predominantly bullish, with 2 Buy/Strong Buy ratings. The consensus 12-month price target of $N/A implies N/A% upside from current levels.
With a forward P/E of 1.0968x, CCM trades at a relatively low valuation. The consensus target of $N/A implies N/A% appreciation, suggesting the market may be pricing in risks.
The most bullish Wall Street analyst has a price target of $N/A for CCM, while the most conservative target is $N/A. The consensus of $N/A represents the median expectation. These targets typically reflect 12-month expectations.
CCM is lightly followed, with 2 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 2 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month CCM stock forecast based on 2 Wall Street analysts shows a consensus price target of $N/A, with estimates ranging from $N/A (bear case) to $N/A (bull case). The median consensus rating is "Buy".
CCM trades at a forward P/E ratio of 1.1x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
CCM appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $N/A target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
CCM analyst price targets range from $N/A to $N/A, a NaN% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $N/A consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.